HFpEF Pharmacotherapy: What a Network Meta-analysis Compared
ABSTRACT:
Study at a glance
- Publication type: Systematic review and network meta-analysis of randomised trials
- What it examined: This network meta-analysis compared established and emerging pharmacotherapies evaluated in randomised trials of heart failure with preserved ejection fraction (HFpEF).
- Key point: The review considered ACE inhibitors, ARBs, beta blockers, MRAs, digoxin, ARNIs, SGLT2 inhibitors, GLP-1 receptor agonists, nitrates and nitrites. Its prespecified outcomes included cardiovascular death or heart failure hospitalisation, mortality, worsening events, functional capacity, quality of life and NT-proBNP.
Why it matters
A comparative evidence review helps place treatments in context, but it does not replace the eligibility criteria, safety monitoring and shared decision-making needed for an individual patient.
Source
Comparative effectiveness of pharmacotherapy for heart failure with preserved ejection fraction: A systematic review and network meta-analysis. PMID: 41588709. View the PubMed record.
This educational summary is based on the cited publication and is not medical advice. Clinical decisions should be made with an appropriately qualified healthcare professional.
